Investigators identified a novel LRRK2 mutation (P1446L) that promotes dopaminergic neuron loss through microglia‑driven inflammation and apoptosis, according to a paper in npj Parkinson’s Disease. The study maps a mechanistic cascade linking the mutation to neuroinflammatory pathways implicated in Parkinson’s disease progression. LRRK2 (leucine‑rich repeat kinase 2) is a kinase genetically tied to familial and sporadic Parkinson’s; the P1446L finding provides a specific pathological mechanism and a potential target for LRRK2‑directed inhibitors. Drug developers and academic groups focused on neurodegeneration can use these data to refine patient stratification and to prioritize anti‑inflammatory or kinase‑modulating interventions for mutation carriers.